Study compares single-inhaler triple therapies for treatment of COPD
For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...
News Medical on MSN3 天
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPD
A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
pharmaphorum3 天
Smart sensor cleared for use with AZ asthma, COPD inhalers
A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers ... disease (COPD). Sales of Breztri ...
pharmaphorum2 天
Verona says COPD drug is off to a flying start
Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...
FiercePharma2 天
Verona touts 'exceptionally strong' launch of blockbuster hopeful COPD treatment Ohtuvayre
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Science Daily5 天
COPD News
New Study Shows Promising Results for COPD Treatment Nov ... Researchers have found that dual bronchodilators -- long-lasting inhalers that relax the airways and make it easier to breathe ...
drugdeliverybusiness2 天
Phillips Medisize enhances inhaled drug delivery portfolio with Vectura acquisition
Phillips Medisize parent company Molex has completed its acquisition of Vectura from a subsidiary of cigarette maker Philip ...
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
Trump took on big tobacco before and won. He can win again by targeting smoking. | Opinion
Making America Healthy Again’ is a complicated, messy, and massive undertaking bound to meet resistance. Reducing nicotine in ...